ITT INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ITT INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.94B | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $3.63B | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $3.28B | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $2.99B | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $2.77B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $2.48B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $2.85B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $2.75B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $2.59B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $2.41B | Feb 22, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.39B | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $1.25B | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $1.11B | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $922.30M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $899.50M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $782.20M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $910.10M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $887.20M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $819.90M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $760.90M | Feb 22, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $488.00M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $519.90M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $412.20M | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $367.00M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $316.30M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $72.50M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $325.10M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $333.70M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $113.50M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $186.10M | Feb 22, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $684.50M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $678.10M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $530.50M | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $468.00M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $504.30M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $226.50M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $411.40M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $397.30M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $319.30M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $276.60M | Feb 22, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.80M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $116.30M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $102.60M | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $96.50M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $94.90M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $84.90M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $97.90M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $98.40M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $93.50M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $80.50M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $1.58B | Feb 24, 2011 |
| FY2009 | Dec 31, 2009 | $1.58B | Mar 1, 2010 |
| FY2009 | Dec 31, 2008 | $1.71B | Mar 1, 2010 |
| FY2009 | Dec 31, 2007 | $1.33B | Mar 1, 2010 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $328.00M | Feb 24, 2011 |
| FY2009 | Dec 31, 2009 | $271.60M | Mar 1, 2010 |
| FY2009 | Dec 31, 2008 | $248.70M | Mar 1, 2010 |
| FY2009 | Dec 31, 2007 | $239.30M | Mar 1, 2010 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.31B | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $4.73B | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | $3.93B | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $3.78B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $3.57B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $4.28B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $4.11B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $3.85B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $3.70B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $3.60B | Feb 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.22B | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $1.95B | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | $1.39B | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $1.52B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $1.33B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $2.15B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $2.03B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $2.02B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $2.10B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $2.17B | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.08B | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $2.78B | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | $2.53B | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $2.25B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $2.23B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $2.13B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $2.07B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $1.82B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $1.60B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $1.43B | Feb 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51B | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $1.43B | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $1.02B | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $964.80M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $924.30M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $944.80M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $927.20M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $875.90M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $886.80M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $774.70M | Feb 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.99B | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $3.12B | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | $2.78B | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $2.51B | Feb 12, 2024 |
| FY2024 | Dec 31, 2021 | $2.46B | Feb 10, 2025 |
| FY2023 | Dec 31, 2020 | $2.32B | Feb 12, 2024 |
| FY2022 | Dec 31, 2019 | $2.37B | Feb 15, 2023 |
| FY2021 | Dec 31, 2018 | $2.11B | Feb 16, 2022 |
| FY2020 | Dec 31, 2017 | $1.86B | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | $1.79B | Feb 21, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.74B | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $439.30M | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | $489.20M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $561.20M | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $647.50M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $859.80M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $612.10M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $561.20M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $389.80M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $460.70M | Feb 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | 3 | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | 3 | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 22, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | 3 | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | 3 | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 22, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | 87.80M | Feb 21, 2020 |
| FY2019 | Dec 31, 2018 | 87.60M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 88.20M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 89.50M | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | 89.50M | Feb 17, 2017 |
| FY2015 | Dec 31, 2014 | 91.00M | Feb 22, 2016 |
| FY2014 | Dec 31, 2013 | 91.00M | Feb 20, 2015 |
| FY2013 | Dec 31, 2012 | 92.10M | Feb 21, 2014 |
| FY2012 | Dec 31, 2011 | 93.50M | Feb 27, 2013 |
| FY2011 | Dec 31, 2010 | 92.60M | Feb 29, 2012 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.00M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $104.70M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $95.80M | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $87.90M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $75.80M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $59.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $52.10M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $47.30M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $45.40M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $44.60M | Feb 22, 2019 |